You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Computational prediction of gut microbiome-mediated drug metabolism

    SBC: NEXILICO, INC.            Topic: 100

    Project Summary / Abstract Notwithstanding pre-clinical experiments and clinical trials performed to identify efficacy, side effects, and adverse drug reactions (ADRs), only 25-60% of patients respond favorably to prescribed drugs, leading to a cost of $30-$130 billion in the US annually. ADRs are partially attributed to the gut microbiome, i.e. the complex and dynamic community of microorganisms ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Multistage LC-MSn for automated glycan isomer assignment of glycopeptides

    SBC: PROTEIN METRICS INC            Topic: 400

    N- and O-linked glycosylation are some of the most common, abundant, and biologically important posttranslational modifications of proteins, yet they are also some of the most difficult to study. The dominant analytical platform for the study of glycosylation is mass spectrometry, yet this platform on its own is incomplete, because it cannot elucidate glycan topology and linkage stereochemistry. T ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Safe in Utero Gene Editing Technology in Mice

    SBC: Acrigen Biosciences, Inc.            Topic: 100

    Abstract In the nearly 20 years since the groundbreaking sequencing of the human genome, the potential for precision genetic medicine has still not been realized. Advances in sequencing have vastly increased our ability to screen patients (including parents and fetuses) for genetic abnormalities, dramatically expanding identification of hereditary diseases in the prenatal period. This opens the do ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Therapeutic Monoclonal Antibody Against EGFL6, a Mediator of Tumor Growth and Metastasis

    SBC: Tradewind BioScience            Topic: 102

    SUMMARY A diagnosis of ovarian cancer (OvCa) is especially devastating. With 22,240 diagnoses in 2018 and an estimated 14,070 deaths, OvCa has the third-highest mortality rate, leading to the fifth-highest number of cancer deaths among women in the United States. The objective of this research is to validate the anti-tumor function of humanized antibodies with the end goal of identifying and devel ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Rapid point-of-care detection of Chlamydia trachomatis in urine

    SBC: ELECTRONUCLEICS INC            Topic: NIAID

    Project Summary The goal of this project is to demonstrate feasibility of a system for the point-of-care (POC) detection of Chlamydia trachomatis (CT) in human urine samples that integrates a patented detector of pathogens based on identification of species-specific, nucleic acid (NA) sequences. The detector relies on a novel electromechanical signal transduction mechanism that enables the low-cos ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II)

    SBC: Tengen Biomedical Co            Topic: NIAID

    Development of Zika viral pseudoinfectious virus as zika vaccine candidate(Phase 2) Abstract Zika virus epidemics and the association of ZIKV infection with Guillain–Barré syndrome, and congenital disabilities, including microcephaly, led the World Health Organization to declare ZIKV a “Public Health Emergency of International Concern” in 2016. Since then, various ZIKV vaccine platforms hav ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Developing a novel drug for neurobehavioral deficits in FASD

    SBC: COGTHERA LLC            Topic: 230

    Project Summary Fetal Alcohol Spectrum Disorder (FASD) is a debilitating condition causing a wide range of disabilities including behavioral and intellectual deficits, facial dysmorphology, and organ malformations. This disorder has a profound impact on health care burden and cost; as many as 5% of children within the United States are affected by this condition, with lifetime treatment costs reac ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Development and Evaluation of a Brief Behavioral Activation Mobile Application for Nicotine Vaping Cessation Among Adolescent Primary Care Patients

    SBC: MOUNTAINPASS TECHNOLOGY LLC            Topic: NIDA

    ABSTRACT The prevalence of vaping nicotine has skyrocketed among adolescents in recent years, yet no NIH-funded trials have developed or evaluated vaping cessation interventions. An ideal treatment must directly target established vaping risk factors. Depressive symptoms, which are common among adolescent vapers (36%), have recently been identified as a predominant vaping-related risk factor. The ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Melanocortin-3 Receptor Peptide Agonists for the Treatment of Anorexia Nervosa

    SBC: COURAGE THERAPEUTICS INC            Topic: 101

    Anorexia nervosa (AN) is a devastating neuropsychiatric disease with a high prevalence (up to 2.2% of women) and significant morbidity and mortality. There are currently no effective therapeutic agents for the disorder. The goal of Courage Therapeutics is the development of melanocortin-3 receptor (MC3R) -specific agonist peptides for the treatment of anorexia nervosa. The product of this Phase I ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Small molecule inhibitors of influenza virus nucleoprotein

    SBC: ALEXANDER BIODISCOVERIES, LLC            Topic: NIAID

    Influenza is a continuing worldwide public health threat, with seasonal activity that is not adequately controlled by the yearly vaccine program. The severity of this problem is likely to increase with emergence of new influenza virus strains in the human population, and this situation is made even more complex by the COVID-19 pandemic. Both COVID-19 and the 2009 H1N1 influenza pandemics are remin ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government